Surrozen, Inc. WarrantSRZNW
About: Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Employees: 41
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 17 [Q4 2024] → 18 (+1) [Q1 2025]
5.62% more ownership
Funds ownership: 88.89% [Q4 2024] → 94.51% (+5.62%) [Q1 2025]
15% less capital invested
Capital invested by funds: $1.02M [Q4 2024] → $867K (-$151K) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for SRZNW.
Financial journalist opinion
We haven’t received any recent news articles for SRZNW.